291 research outputs found
H.264 fast intra mode selection algorithm based on direction difference measure in the pixel domain
2009 IEEE International Conference on Acoustics, Speech, and Signal Processing, ICASSP 2009, Taipei, 19-24 April 2009In this paper, a fast mode decision algorithm for Intra prediction in the H.264/AVC is proposed. We use the characteristics of each directional prediction mode to compute the strength of directional differences in the original pixel domain to find the minimal direction error. This is the first time reported in the literature that the intrinsic differences between the real-data and the predictors of modes are used to form an algorithm for mode decision. The approach allows us to select several better candidate modes for evaluation instead of using the full search. Experimental results show that the proposed method can achieve more than 80% reduction in computation with negligible degradation in rate-distortion performance, and the results are better than other algorithms available in the literature.Department of Electronic and Information EngineeringRefereed conference pape
Intensive chemotherapy with peripheral blood stem cell (PBSC) support in the treatment of leukemia relapse after allogeneic bone marrow transplantation: clinical results and chimerism findings
published_or_final_versio
Intensive chemotherapy with peripheral blood stem cell (PBSC) support in the treatment of leukemia relapse after allogeneic bone marrow transplantation: clinical results and chimerism findings
published_or_final_versio
Overexpression of Forkhead Box Protein M1 (FOXM1) in Ovarian Cancer Correlates with Poor Patient Survival and Contributes to Paclitaxel Resistance
published_or_final_versio
A new concurrent chemotherapy with vinorelbine and mitomycin C in combination with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck
Objective: The purpose of this pilot study was to evaluate the feasibility and toxicity of concurrent chemotherapy with vinorelbine and mitomycin C in combination with accelerated radiotherapy (RT) in patients with locally advanced cancer of the head and neck. Patients and Methods: Between January 2003 and March 2004, 15 patients with T4/N2-3 squamous cell carcinoma (12/15) and with N3 cervical lymph node metastases of carcinoma of unknown primary (3/15) were treated with chemotherapy and simultaneous accelerated RT. Results: 11 patients completed therapy without interruption or dose reduction. Grade 3 - 4 acute mucosal toxicity was observed in 9/15 patients, grade 4 hematologic toxicity in 6/15 patients. At a median follow-up of 7.5 months, 2 patients have died of intercurrent disease, 2 patients have experienced local relapse; 5 patients are alive with no evidence of disease at the primary tumor site. Discussion: The described regimen is highly effective, but led to remarkable side effects
First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the survivin vaccine
How to misuse echo contrast
<p>Abstract</p> <p>Background</p> <p>Primary intracardiac tumours are rare, there are however several entities that can mimic tumours. Contrast echocardiography has been suggested to aid the differentiation of various suspected masses. We present a case where transthoracic echocardiography completely misdiagnosed a left atrial mass, partly due to use of echo contrast.</p> <p>Case presentation</p> <p>An 80 year-old woman was referred for transthoracic echocardiography because of one-month duration of worsening of dyspnoea. Transthoracic echocardiography displayed a large echodense mass in the left atrium. Intravenous injection of contrast (SonoVue, Bracco Inc., It) indicated contrast-enhancement of the structure, suggesting tumour. Transesophageal echocardiography revealed, however, a completely normal finding in the left atrium. Subsequent gastroscopy examination showed a hiatal hernia.</p> <p>Conclusion</p> <p>It is noteworthy that the transthoracic echocardiographic exam completely misdiagnosed what seemed like a left atrial mass, which in part was an effect of the use of echo contrast. This example highlights that liberal use of transoesophageal echocardiography is often warranted if optimal display of cardiac structures is desired.</p
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
Background: Brivanib is a selective inhibitor of vascular endothelial growth factor
and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discontinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas [STS], ovarian cancer, breast
cancer, pancreatic cancer, non-small-cell lung cancer [NSCLC], gastric/esophageal cancer and
transitional cell carcinoma [TCC]).
Patients and methods: During a 12-week open-label lead-in period, patients received brivanib
800 mg daily and were evaluated for FGF2 status by immunohistochemistry. Patients with stable disease at week 12 were randomised to brivanib or placebo. A study steering committee
evaluated week 12 response to determine if enrolment in a tumour type would continue.
The primary objective was progression-free survival (PFS) for brivanib versus placebo in patients with FGF2-positive tumours.
Results: A total of 595 patients were treated, and stable disease was observed at the week 12
randomisation point in all tumour types. Closure decisions were made for breast cancer,
pancreatic cancer, NSCLC, gastric cancer and TCC. Criteria for expansion were met for
STS and ovarian cancer. In 53 randomised patients with STS and FGF2-positive tumours,
the median PFS was 2.8 months for brivanib and 1.4 months for placebo (hazard ratio
[HR]: 0.58, p Z 0.08). For all randomised patients with sarcomas, the median PFS was 2.8
months (95% confidence interval [CI]: 1.4e4.0) for those treated with brivanib compared with
1.4 months (95% CI: 1.3e1.6) for placebo (HR Z 0.64, 95% CI: 0.38e1.07; p Z 0.09). In the
36 randomised patients with ovarian cancer and FGF2-positive tumours, the median PFS was
4.0 (95% CI: 2.6e4.2) months for brivanib and 2.0 months (95% CI: 1.2e2.7) for placebo (HR:
0.56, 95% CI: 0.26e1.22). For all randomised patients with ovarian cancer, the median PFS in
those randomised to brivanib was 4.0 months (95% CI: 2.6e4.2) and was 2.0 months (95% CI:
1.2e2.7) in those randomised to placebo (HR Z 0.54, 95% CI: 0.25e1.17; p Z 0.11).
Conclusion: Brivanib demonstrated activity in STS and ovarian cancer with an acceptable
safety profile. FGF2 expression, as defined in the protocol, is not a predictive biomarker of
the efficacy of brivanib
TSPYL2 Is Important for G1 Checkpoint Maintenance upon DNA Damage
Nucleosome assembly proteins play important roles in chromatin remodeling, which determines gene expression, cell proliferation and terminal differentiation. Testis specific protein, Y-encoded-like 2 (TSPYL2) is a nucleosome assembly protein expressed in neuronal precursors and mature neurons. Previous studies have shown that TSPYL2 binds cyclin B and inhibits cell proliferation in cultured cells suggesting a role in cell cycle regulation. To investigate the physiological significance of TSPYL2 in the control of cell cycle, we generated mice with targeted disruption of Tspyl2. These mutant mice appear grossly normal, have normal life span and do not exhibit increased tumor incidence. To define the role of TSPYL2 in DNA repair, checkpoint arrest and apoptosis, primary embryonic fibroblasts and thymocytes from Tspyl2 deficient mice were isolated and examined under unperturbed and stressed conditions. We show that mutant fibroblasts are impaired in G1 arrest under the situation of DNA damage induced by gamma irradiation. This is mainly attributed to the defective activation of p21 transcription despite proper p53 protein accumulation, suggesting that TSPYL2 is additionally required for p21 induction. TSPYL2 serves a biological role in maintaining the G1 checkpoint under stress condition
Epigenetic Inactivation of the miR-124-1 in Haematological Malignancies
miR-124-1 is a tumour suppressor microRNA (miR). Epigenetic deregulation of miRs is implicated in carcinogenesis. Promoter DNA methylation and histone modification of miR-124-1 was studied in 5 normal marrow controls, 4 lymphoma, 8 multiple myeloma (MM) cell lines, 230 diagnostic primary samples of acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), MM, and non-Hodgkin's lymphoma (NHL), and 53 MM samples at stable disease or relapse. Promoter of miR-124-1 was unmethylated in normal controls but homozygously methylated in 4 of 4 lymphoma and 4 of 8 myeloma cell lines. Treatment of 5-Aza-2′-deoxycytidine led to miR-124-1 demethylation and re-expression of mature miR-124, which also associated with emergence of euchromatic trimethyl H3K4 and consequent downregulation of CDK6 in myeloma cells harboring homozygous miR-124-1 methylation. In primary samples at diagnosis, miR-124-1 methylation was absent in CML but detected in 2% each of MM at diagnosis and relapse/progression, 5% ALL, 15% AML, 14% CLL and 58.1% of NHL (p<0.001). Amongst lymphoid malignancies, miR-124-1 was preferentially methylated in NHL than MM, CLL or ALL. In primary lymphoma samples, miR-124-1 was preferentially hypermethylated in B- or NK/T-cell lymphomas and associated with reduced miR-124 expression. In conclusion, miR-124-1 was hypermethylated in a tumour-specific manner, with a heterochromatic histone configuration. Hypomethylation led to partial restoration of euchromatic histone code and miR re-expression. Infrequent miR-124-1 methylation detected in diagnostic and relapse MM samples showed an unimportant role in MM pathogenesis, despite frequent methylation found in cell lines. Amongst haematological cancers, miR-124-1 was more frequently hypermethylated in NHL, and hence warrants further study
- …